Regeneron Pharmaceuticals Inc

Healthcare · Biotechnology

726.50$ -1.2% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Income Statement

Regeneron Pharmaceuticals Inc (REGN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 4,291 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement REGN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	1,220	1,227	1,319	1,470	1,501	1,582	1,511	1,608	1,663	1,928	1,373	1,578	1,744	1,864	1,828	1,952	2,294	2,423	2,529	5,139	3,453	4,952	2,965	2,857	2,936	3,414	3,162	3,158	3,363	3,434	3,145	3,547	3,721	3,789	3,029	3,676	3,754	3,884	3,605	4,291	15,535
Cost of Revenue	72	104	122	138	142	140	151	125	146	160	223	198	278	276	273	334	333	415	375	765	526	1,057	479	372	410	507	557	508	542	629	434	480	491	565	464	530	522	585	669	577	2,352
Gross Profit	1,148	1,123	1,197	1,332	1,359	1,442	1,360	1,483	1,518	1,768	1,150	1,380	1,465	1,588	1,555	1,618	1,961	2,008	2,153	4,374	2,926	3,895	2,486	2,486	2,526	2,907	2,605	2,650	2,821	2,805	2,711	3,067	3,230	3,224	2,564	3,145	3,233	3,300	2,936	3,714	13,183
Research & Development	515	450	469	475	492	493	462	496	522	558	435	833	473	683	528	663	625	683	676	643	592	711	770	720	819	942	1,002	982	970	1,051	1,256	1,224	1,328	1,426	1,340	1,432	1,558	1,626	1,645	1,632	6,461
Selling, General & Administrative	270	326	297	307	307	410	331	365	369	491	411	417	420	587	367	348	327	367	406	415	445	560	450	476	529	661	601	652	641	738	689	759	714	792	633	634	658	775	648	662	2,743
Total Operating Expenses	785	776	766	782	799	903	793	861	891	1,050	670	1,064	727	912	855	961	908	841	1,041	1,027	1,079	1,255	1,199	1,179	1,302	1,592	1,602	1,634	1,610	1,755	1,960	1,997	2,050	2,234	1,973	2,066	2,206	2,420	2,293	2,294	9,213
Operating Income	363	347	431	550	560	539	567	622	627	718	480	316	739	676	700	656	1,053	1,167	1,113	3,347	1,847	2,640	1,287	1,307	1,224	1,315	1,003	1,017	1,211	1,051	751	1,070	1,180	990	592	1,080	1,027	880	643	1,421	3,970
Interest Expense	0.5	3.4	7.5	5.4	6.2	6.0	6.4	6.9	7.5	7.3	7.7	8.0	7.8	6.7	6.1	9.7	26	15	15	14	14	14	14	13	15	17	18	19	18	18	16	15	14	11	8.7	3.6	19	12	13	11	55
Pre-Tax Income	366	342	432	526	566	555	585	656	636	676	546	225	769	890	669	919	998	1,225	1,253	3,753	1,817	2,503	1,061	963	1,510	1,325	858	1,083	1,111	1,148	701	1,628	1,493	958	905	1,519	1,763	1,044	831	1,528	5,166
Income Tax Expense	101	88	183	138	177	381	107	105	41	-144	85	32	99	98	44	22	156	75	138	654	184	274	88	111	194	128	40	115	103	-12	-21	196	152	40	96	127	303	199	104	231	837
Net Income	265	253	249	388	388	174	478	551	595	820	461	193	670	792	625	897	842	1,149	1,115	3,099	1,632	2,229	974	852	1,316	1,197	818	968	1,008	1,160	722	1,432	1,341	918	809	1,392	1,460	845	727	1,297	4,329
EBITDA	394	370	478	566	610	595	628	697	679	726	605	285	829	951	731	987	1,084	1,301	1,335	3,838	1,904	2,592	1,149	1,051	1,618	1,442	976	1,205	1,234	1,279	831	1,764	1,629	1,095	1,041	1,657	1,919	1,201	967	1,663	5,750

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings